Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol Versus Dexmedetomidine for Sedation During Chronic Subdural Hematoma Surgery
NCT07912203Phase 4Not yet recruiting
- Sponsor
- National Institute of Neurology, Tunisia
- Start
- Nov 2026
- Primary completion
- Apr 2027
01
Overview
Phase 4, randomised, triple-blind trial of dexmedetomidine and propofol injection (veterinary) in chronic subdural hematoma (CSDH), sponsored by National Institute of Neurology, Tunisia. Primary endpoint: Percentage of time within target sedation. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dexmedetomidinepropofol injection (veterinary)
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT07912203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07912203.